Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 211

Similar articles for PubMed (Select 21327941)


Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.

Jones DT, Mulholland SA, Pearson DM, Malley DS, Openshaw SW, Lambert SR, Liu L, Bäcklund LM, Ichimura K, Collins VP.

Acta Neuropathol. 2011 Jun;121(6):753-61. doi: 10.1007/s00401-011-0810-6. Epub 2011 Feb 17.


MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.

Groenendijk FH, Taal W, Dubbink HJ, Haarloo CR, Kouwenhoven MC, van den Bent MJ, Kros JM, Dinjens WN.

J Neurooncol. 2011 Feb;101(3):405-17. doi: 10.1007/s11060-010-0274-x. Epub 2010 Jul 1.


IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.

Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW.

Cancer. 2012 Jan 15;118(2):452-60. doi: 10.1002/cncr.26298. Epub 2011 Jun 29.


MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.

Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, Bäcklund LM, Collins VP, Ichimura K.

Int J Cancer. 2012 Sep 1;131(5):1104-13. doi: 10.1002/ijc.26499. Epub 2012 Jan 11.


MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.


IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D.

J Neurooncol. 2011 Nov;105(2):345-57. doi: 10.1007/s11060-011-0596-3. Epub 2011 Jun 4.


WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.

Rauscher J, Beschorner R, Gierke M, Bisdas S, Braun C, Ebner FH, Schittenhelm J.

J Clin Pathol. 2014 Jul;67(7):556-61. doi: 10.1136/jclinpath-2013-202114. Epub 2014 Mar 7.


Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.

Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM, Fleming A, Hadjadj D, Schwartzentruber J, Majewski J, Dong Z, Siegel P, Albrecht S, Croul S, Jones DT, Kool M, Tonjes M, Reifenberger G, Faury D, Zadeh G, Pfister S, Jabado N.

Acta Neuropathol. 2012 Nov;124(5):615-25. doi: 10.1007/s00401-012-1031-3. Epub 2012 Aug 12.


Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M.

J Clin Oncol. 2009 Dec 1;27(34):5743-50. doi: 10.1200/JCO.2009.23.0805. Epub 2009 Oct 5.


Clinicopathologic and genomic features of gliosarcomas.

Lee D, Kang SY, Suh YL, Jeong JY, Lee JI, Nam DH.

J Neurooncol. 2012 May;107(3):643-50. doi: 10.1007/s11060-011-0790-3. Epub 2012 Jan 20.


Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY.

J Clin Oncol. 2009 Sep 1;27(25):4150-4. doi: 10.1200/JCO.2009.21.9832. Epub 2009 Jul 27.


Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.

Huang L, Jiang T, Yuan F, Li GL, Cui Y, Liu EZ, Wang ZC.

Neuropathol Appl Neurobiol. 2009 Aug;35(4):367-79. doi: 10.1111/j.1365-2990.2008.01002.x. Epub 2008 Nov 18.


Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.

Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H, Giangaspero F.

J Neurooncol. 2010 Sep;99(2):209-15. doi: 10.1007/s11060-010-0129-5. Epub 2010 Feb 21.


Molecular profile of oligodendrogliomas in young patients.

Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V, Shukla S, Somasundaram K, Mahapatra AK, Kale SS, Sarkar C.

Neuro Oncol. 2011 Oct;13(10):1099-106. doi: 10.1093/neuonc/nor146.


IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.

Neurology. 2010 Oct 26;75(17):1560-6. doi: 10.1212/WNL.0b013e3181f96282.


Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.

Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M; German Glioma Network.

Clin Cancer Res. 2013 Sep 15;19(18):5146-57. doi: 10.1158/1078-0432.CCR-13-0017. Epub 2013 Aug 5.


IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.

Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16.


Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.

Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J, Reifenberger G, Tonn JC, Kretzschmar HA.

Int J Cancer. 2007 Dec 1;121(11):2458-64.


IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.

Kalkan R, Atli Eİ, Özdemir M, Çiftçi E, Aydin HE, Artan S, Arslantaş A.

Gene. 2015 Jan 1;554(1):81-6. doi: 10.1016/j.gene.2014.10.027. Epub 2014 Oct 14.


Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A.

Acta Neuropathol. 2010 Dec;120(6):707-18. doi: 10.1007/s00401-010-0781-z. Epub 2010 Nov 19.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk